Financial Times
UK · 4 hrs ago
AstraZeneca investors raise concerns over mega-merger talks
Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers Squibb
Do you trust Financial Times?
Sign in to rate
Discussion
?
No comments yet — be the first to start the discussion!